# Canopy Growth Corp: overview

CGC · Nasdaq · CIK 1737927 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Mar 31

Pages: [Overview](/companies/cgc.md) · [Financials](/companies/cgc/financials.md) · [Filings](/companies/cgc/filings.md) · [Insiders](/companies/cgc/insiders.md)

Latest reported revenue: [CAD 81.2m](/filings/0001193125-26-339076.md) for Q1 FY2027, three months to 2026-06-30, from the 10-Q filed Aug 7, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-339076).

## Last eight quarters

| Line item | Unit | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | Q4 FY2025 (2025-03-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | Q4 FY2026 (2026-03-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [63.0](/filings/0001193125-26-270260.md) | [74.8](/filings/0001193125-26-270260.md) | [65.0 d](/filings/0001193125-26-270260.md) | [72.1](/filings/0001193125-26-339076.md) | [66.7](/filings/0001193125-26-270260.md) | [74.5](/filings/0001193125-26-270260.md) | [71.2 d](/filings/0001193125-26-270260.md) | [81.2](/filings/0001193125-26-339076.md) |
| Gross margin | % | [34.7%](/filings/0001193125-26-270260.md) | [32.2%](/filings/0001193125-26-270260.md) | [16.2% d](/filings/0001193125-26-270260.md) | [25.0%](/filings/0001193125-26-339076.md) | [32.8%](/filings/0001193125-26-270260.md) | [28.8%](/filings/0001193125-26-270260.md) | [11.6% d](/filings/0001193125-26-270260.md) | [27.4%](/filings/0001193125-26-339076.md) |
| Operating margin | % | [(72.9%)](/filings/0001193125-26-270260.md) | [(31.9%)](/filings/0001193125-26-270260.md) | [(28.1%) d](/filings/0001193125-26-270260.md) | [(31.4%)](/filings/0001193125-26-339076.md) | [(25.3%)](/filings/0001193125-26-270260.md) | [(35.3%)](/filings/0001193125-26-270260.md) | [(134.5%) d](/filings/0001193125-26-270260.md) | [(27.2%)](/filings/0001193125-26-339076.md) |
| Net margin | % | [(173.0%)](/filings/0001193125-26-270260.md) | [(131.2%)](/filings/0001193125-26-270260.md) | [(301.3%) d](/filings/0001193125-26-270260.md) | [(62.2%)](/filings/0001193125-26-339076.md) | [(7.5%) d](/filings/0001193125-26-270260.md) | [(78.3%) d](/filings/0001193125-26-270260.md) | [(217.2%) d](/filings/0001193125-26-270260.md) | [(18.0%)](/filings/0001193125-26-339076.md) |
| Diluted EPS | $ per share | [(1.26)](/filings/0001193125-26-270260.md) | [(0.89)](/filings/0001193125-26-270260.md) | not reported | [(0.24)](/filings/0001193125-26-339076.md) | [(0.02)](/filings/0001193125-26-270260.md) | [(0.17)](/filings/0001193125-26-270260.md) | not reported | [(0.03)](/filings/0001193125-26-339076.md) |
| Free cash flow | $m | [(56.4) d](/filings/0001193125-26-270260.md) | [(28.2) d](/filings/0001193125-26-270260.md) | [(36.2) d](/filings/0001193125-26-270260.md) | [(11.6)](/filings/0001193125-26-339076.md) | [(19.2) d](/filings/0001193125-26-270260.md) | [(19.0) d](/filings/0001193125-26-270260.md) | [(19.3) d](/filings/0001193125-26-270260.md) | [(25.7)](/filings/0001193125-26-339076.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:ProfitLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure; 9-month figure less the 6-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 6-month figure less the 3-month figure; 9-month figure less the 6-month figure; 12-month figure less the 9-month figure.

## Last five fiscal years

| Line item | Unit | FY2022 (2022-03-31) | FY2023 (2023-03-31) | FY2024 (2024-03-31) | FY2025 (2025-03-31) | FY2026 (2026-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [476](/filings/0000950170-24-066240.md) | [333](/filings/0000950170-25-079317.md) | [297](/filings/0001193125-26-270260.md) | [269](/filings/0001193125-26-270260.md) | [285](/filings/0001193125-26-270260.md) |
| Gross margin | % | [(39.4%)](/filings/0000950170-24-066240.md) | [(19.1%)](/filings/0000950170-25-079317.md) | [27.2%](/filings/0001193125-26-270260.md) | [29.6%](/filings/0001193125-26-270260.md) | [24.5%](/filings/0001193125-26-270260.md) |
| Operating margin | % | [(214.2%)](/filings/0000950170-24-066240.md) | [(789.3%)](/filings/0000950170-25-079317.md) | [(77.0%)](/filings/0001193125-26-270260.md) | [(43.5%)](/filings/0001193125-26-270260.md) | [(56.8%)](/filings/0001193125-26-270260.md) |
| Net margin | % | [(69.5%)](/filings/0000950170-24-066240.md) | [(993.1%)](/filings/0000950170-25-079317.md) | [(239.7%)](/filings/0001193125-26-270260.md) | [(189.2%)](/filings/0001193125-26-270260.md) | [(92.4%)](/filings/0001193125-26-270260.md) |
| Diluted EPS | $ per share | [(7.92)](/filings/0000950170-24-066240.md) | [(70.69)](/filings/0000950170-25-079317.md) | [(9.27)](/filings/0001193125-26-270260.md) | [(4.73)](/filings/0001193125-26-270260.md) | [(0.88)](/filings/0001193125-26-270260.md) |
| Free cash flow | $m | [(582)](/filings/0000950170-24-066240.md) | [(567)](/filings/0000950170-25-079317.md) | [(285)](/filings/0001193125-26-270260.md) | [(177)](/filings/0001193125-26-270260.md) | [(69.1)](/filings/0001193125-26-270260.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:ProfitLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/cgc/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [Tidal Investments LLC](/funds/1600064.md) | 2026-06-30 | $8.7m | 9,189,630 |  | Added +709,737 |
| [GFS Advisors, LLC](/funds/1427263.md) | 2026-06-30 | $6.7m | 27 |  | New +27 |
| [SUSQUEHANNA INTERNATIONAL GROUP, LLP](/funds/1446194.md) | 2026-06-30 | $2.2m | 2,315,600 | Call | Added +1,087,500 |
| [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $1.8m | 1,946,294 |  | Reduced −23,346 |
| [LAZARD ASSET MANAGEMENT LLC](/funds/1207017.md) | 2026-06-30 | $1.8m | 1,847,500 |  | Added +39,514 |
| [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $1.5m | 1,562,808 |  | Reduced −19,504 |
| [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $1.3m | 1,396,338 |  | Added +456,939 |
| [GOLDMAN SACHS GROUP INC](/funds/886982.md) | 2026-06-30 | $1.2m | 1,303,720 |  | Added +40,118 |
| [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $1.2m | 1,254,500 | Call | Reduced −197,100 |
| [SUSQUEHANNA INTERNATIONAL GROUP, LLP](/funds/1446194.md) | 2026-06-30 | $1.2m | 1,219,106 |  | Added +238,530 |

## Recent filings

[All 758 filings](/companies/cgc/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-23 | 17:19 ET | [8-K](/filings/0001104659-26-118521.md) | 5.07 Shareholder vote results | 0001104659-26-118521 |
| 2026-10-16 | 21:00 ET | [8-K](/filings/0001104659-26-116639.md) | 3.01 Delisting notice | 0001104659-26-116639 |
| 2026-08-07 | 20:50 ET | [DEF 14A](/filings/0001104659-26-092759.md) | Proxy statement, period 2026-09-25 | 0001104659-26-092759 |
| 2026-08-07 | 20:05 ET | [8-K](/filings/0001104659-26-092687.md) | 4.01 Change of auditor; 9.01 Financial statements and exhibits | 0001104659-26-092687 |
| 2026-08-07 | 11:05 ET | [8-K](/filings/0001193125-26-339131.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-339131 |
| 2026-08-07 | 10:45 ET | [10-Q](/filings/0001193125-26-339076.md) | Quarterly report, period 2026-06-30 | 0001193125-26-339076 |
| 2026-06-15 | 11:06 ET | [8-K](/filings/0001193125-26-270277.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-270277 |
| 2026-06-15 | 10:46 ET | [10-K](/filings/0001193125-26-270260.md) | Annual report, period 2026-03-31 | 0001193125-26-270260 |
| 2026-05-27 | 20:16 ET | [8-K](/filings/0001104659-26-066964.md) | 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001104659-26-066964 |
| 2026-05-15 | 21:06 ET | [8-K](/filings/0001104659-26-062784.md) | 4.02 Non-reliance on financial statements; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-26-062784 |

## Latest annual report

[Form 10-K for the fiscal year ended Mar 31, 2026](/filings/0001193125-26-270260.md), filed Jun 15, 2026.

## Forecast league

Q2 FY2027, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/152209af-4402-4135-9986-2e9e0b9a907e)

## About the filer

- CIK: 1737927
- Tickers: CGC
- Exchange: Nasdaq
- SIC code: 2833 Medicinal Chemicals & Botanical Products
- State of incorporation: Z4
- Filer category: Accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.